10,369 Shares in Inari Medical, Inc. (NASDAQ:NARI) Acquired by Aigen Investment Management LP

Aigen Investment Management LP purchased a new stake in Inari Medical, Inc. (NASDAQ:NARI - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,369 shares of the company's stock, valued at approximately $428,000.

Several other institutional investors have also made changes to their positions in the stock. GAMMA Investing LLC raised its holdings in Inari Medical by 164.7% in the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company's stock valued at $34,000 after acquiring an additional 438 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in Inari Medical by 83.5% in the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company's stock valued at $46,000 after purchasing an additional 435 shares in the last quarter. Covestor Ltd lifted its position in Inari Medical by 30.2% during the first quarter. Covestor Ltd now owns 1,619 shares of the company's stock worth $78,000 after purchasing an additional 376 shares during the period. Benjamin F. Edwards & Company Inc. grew its stake in Inari Medical by 39.4% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company's stock worth $89,000 after buying an additional 522 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Inari Medical in the 2nd quarter valued at about $104,000. 90.98% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on NARI. Deutsche Bank Aktiengesellschaft began coverage on shares of Inari Medical in a research report on Friday, August 9th. They set a "buy" rating and a $68.00 price target on the stock. Stifel Nicolaus initiated coverage on Inari Medical in a report on Tuesday, September 17th. They issued a "hold" rating and a $50.00 target price on the stock. Truist Financial boosted their price target on Inari Medical from $46.00 to $50.00 and gave the stock a "hold" rating in a report on Tuesday, October 29th. Needham & Company LLC reaffirmed a "hold" rating on shares of Inari Medical in a research note on Tuesday, October 29th. Finally, William Blair assumed coverage on Inari Medical in a research note on Thursday, July 25th. They set an "outperform" rating for the company. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Inari Medical has an average rating of "Hold" and an average price target of $58.89.

Inari Medical Price Performance

NASDAQ NARI traded up $1.32 during trading hours on Friday, reaching $50.56. The company's stock had a trading volume of 703,356 shares, compared to its average volume of 991,420. The firm has a fifty day simple moving average of $45.19 and a 200-day simple moving average of $46.94. Inari Medical, Inc. has a 52 week low of $36.73 and a 52 week high of $67.13. The stock has a market cap of $2.96 billion, a P/E ratio of -37.45 and a beta of 0.96.

Insider Buying and Selling at Inari Medical

In other Inari Medical news, Director William Hoffman sold 40,000 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $45.83, for a total transaction of $1,833,200.00. Following the completion of the sale, the director now owns 643,296 shares of the company's stock, valued at approximately $29,482,255.68. This represents a 5.85 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Mitch C. Hill sold 3,000 shares of the company's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $45.13, for a total transaction of $135,390.00. Following the completion of the sale, the chief financial officer now directly owns 179,600 shares in the company, valued at approximately $8,105,348. This represents a 1.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 126,000 shares of company stock worth $5,921,390. 10.60% of the stock is currently owned by company insiders.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.